Table 1 Sex, risk factors, clinical symptoms, site of management, and classification of the study population
From: Acute phase reactants in non-COVID-19 community-acquired pneumonia
Count | % | ||
|---|---|---|---|
Sex | Male | 29 | 56.9% |
Female | 22 | 43.1% | |
Smoking | Yes | 28 | 54.9% |
No | 23 | 45.1% | |
DM | Yes | 23 | 45.1% |
No | 28 | 54.9% | |
Malignancy | Yes | 0 | 0% |
No | 51 | 100% | |
COPD | Yes | 20 | 39.2% |
No | 31 | 60.8% | |
Cough | Productive | 46 | 90.2% |
dry | 5 | 9.8% | |
Dyspnea | Yes | 20 | 39.2% |
No | 31 | 60.8% | |
Chest pain | Yes | 22 | 43.1% |
No | 29 | 56.9% | |
Fever | Yes | 47 | 92.2% |
No | 4 | 7.8% | |
Site of management | Hospital admission | 44 | 86.3% |
Outpatient | 7 | 13.7% | |
Classification of cases | Pneumonia only | 33 | 64.7% |
Pneumonia + empyema and/or complicated parapneumonic effusion | 18 | 35.3% | |
Radiological findings | Lobar consolidation (one lobe involved) | 42 | 82.3% |
Bilateral and/or multi-lobar consolidation | 9 | 17.7% | |
Pleural effusion | 18 | 35.3% | |
Cavitation | 4 | 7.8% | |
Bronchiolar dilation | 2 | 3.9% | |